[Dkt. 9189]

Detroit Auto Dealers Association, Inc., et al.; Prohibited Trade Practices and Affirmative Corrective Actions

AGENCY: Federal Trade Commission.

ACTION: Modified Final Order.

SUMMARY: This order modifies an earlier Commission order to require, for one year, that the automobile dealership and dealership owner respondents involved in the proceeding open their showrooms for a minimum of 64 hours per week, or, at their option, to maintain minimum hours of operation of an average of ten and one half hours per day on weekdays, plus a minimum of eight hours on Saturdays. In addition, the Commission modifies Part VII.D of the Final Order, issued in 1989, by changing from 30 days to 60 days the time period within which the dealership association respondent must investigate and resolve allegations that association members have violated by-laws, rules, or regulations affected by the order.

DATES: Final order issued February 22, 1989. Modified final order issued June 20, 1995.[1]

FOR FURTHER INFORMATION CONTACT: Ernest Nagata, FTC/H–394, Washington, D.C. 20580. (202) 326–2714.

SUPPLEMENTARY INFORMATION: In the Matter of Detroit Auto Dealers Association, Inc., et al. The prohibited trade practices and/or corrective actions as set forth at 54 FR 14337, are changed in part.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 95–21161 Filed 8–24–95; 8:45 am]

BILLING CODE 6750–01–M

[1] Copies of the Order and the Opinion of the Commission, are available from the Commission's Public Reference Branch, H–130, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

Advisory Committee on Childhood Lead Poisoning Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Committee on Childhood Lead Poisoning Prevention.

Times and Dates: 8:30 a.m.–5 p.m., September 12, 1995; 8:30 a.m.–12 noon, September 13, 1995.

Place: Holiday Inn Atlanta—Peachtree Corners, 6050 Peachtree Industrial Boulevard, NW, Norcross, Georgia 30071.

Status: Open to the public, limited only by the space available.

Supplementary Information: In October 1991 the Secretary of Health and Human Services released the CDC policy statement ''Preventing Lead Poisoning in Young Children.'' This statement is used by pediatricians and lead screening programs throughout the United States, and great progress has been made in implementing the statement. Copies of this statement may be requested from the contact person listed below.

Matters to be Discussed

Since the release of this statement, new data have become available and some information gaps have been identified. The Committee will continue to discuss issues related to revising the statement, particularly the blood lead screening guidelines.

Agenda items are subject to change as priorities dictate.

Persons wishing to make written comments regarding additions or changes to the statement should provide such written comments to the contact person no later than September 5, 1995.

Opportunities will be provided during the meeting for oral comments. Depending on the time available and the number of requests, it may be necessary to limit the time of each presenter.

Contact Person for More Information: Barbara Nelson, Program Analyst, Lead Poisoning Prevention Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F42), Atlanta, Georgia 30341–3724, telephone 404/448–7330, FAX 404/488–7335.

Dated: August 17, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–21136 Filed 8–24–95; 8:45 am]

BILLING CODE 4163–18–M

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Health Statistics for Minority and Other Special Populations: Meeting

Pursuant to Pub. L. 92–463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meeting.

Name: NCVHS Subcommittee on Health Statistics for Minority and Other Special Populations.

Time and Date: 8:30 a.m.–4:30 p.m., September 28, 1995.

Place: Room 503A–529A, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

Status: Open

Purpose: The subcommittee will investigate racial disparities among the insured population and will be briefed on the status of the Report to the Assistant Secretary on Socioeconomic Status and the Health of Americans. The subcommittee will review progress in the effort to improve racial and ethnic identification on the Social Security Administration and the Health Care Financing Administration's administrative records and results from the U.S. Census Bureau studies designed to evaluate the use of multi-racial categories in population surveys.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, MD 20782, telephone 301/436–7050.

Dated: August 21, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–21138 Filed 8–24–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0271]

Drug Export; Anzemet (Dolasetron Mesilate) Tablets 25 mg, 50 mg, 100 mg, 200 mg

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Marion Merrell Dow Inc., has filed an application requesting conditional approval for the export of the human drug Anzemet (dolasetron mesilate) Tablets to France for packaging and transshipment to the United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of